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Abstract 
Purpose: To design a dual inhibitor of natural origin capable of targeting ErbB1 and ErbB2 kinases for 
the treatment of lung cancer.  
Method: Advanced In silico drug designing techniques were explored in this study. Sequence and 
structure analysis of ErbB1 and ErbB2 was followed by three dimensional (3D) pharmacophore. The 
generated model was used for molecular docking simulation studies for predicting the best natural dual 
inhibitors, the selected inhibitors were subjected to absorption, distribution, metabolism, excretion and 
toxicology (ADME/Tox) prediction.  
Results: The results confirmedfive phytochemicals, viz. hyoscyamide, cannabisin F, cochinchinenene 
D, cannabisin E, and heliotropamide and five FDA approved drugs namely fesoterodine, antrafenine, 
fluspirilene, posaconazole, and iloprost to be potential inhibitors of both ErbB1 and ErbB2. The 
shortlisted compounds from both the panels were showing better MolDock score than the two reference 
drugs (Lapatinib and Afatinib). 
Conclusion: The 3D pharmacophore modelling and molecular docking simulations gave us ten 
compounds that successfully exploited dual inhibition of ErbB1 and ErbB2. With 8 and 12 hydrogen 
bonds with ErbB1 and ErbB2 respectively cannabisin F showed best interaction of all.  
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The incidence of lung cancer worldwide is 13 %. 
The highest incidence is in developed countries, 
particularly in North America and Europe, and is 
less common in developing and underdeveloped 
countries [1-3]. The etiology of this malady is 
linked with the anomaly in around 26 genes, 
among them receptor tyrosine kinases (RTKs), 
are involved in lung cancer proliferation [4,5]. 
RTKs belong to epidermal growth factor receptor 
family and there four structurally related family 
members are ErbB1 (also known as EGFR or 
Her1), ErbB2 (also known as Her2 or Neu,), 
ErbB3 (also known as Her3), and ErbB4 (also 
known as Her4). Among these, ErbB1 and ErbB2 
are predominant in lung cancer [2,6-8]. These 
kinases have an extracellular ligand binding 
domain, a single hydrophobic transmembrane 
domain, and an intracellular tyrosine kinase 
domain [9]. The success rate of antibody 
treatment targeting the extracellular ligand 
binding domain is low [6]. The tyrosine kinase 
domain, which is structurally conserved in both 
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ErbB1 and ErbB2, is the target site for most of 
the successful anti-cancer drugs which block its 
kinase activity. Many previous studies have 
adapted a dual targeting approach—inhibiting 
ErbB1 and ErbB2 concurrently–which provides 
synergistic inhibition [10,11]. The current study 
also follows the same approach, but the 
difference being that we focus on single inhibitor 
targeting both proteins, unlike the previous 
approaches which have considered individual 






The primary sequences of ErbB1 (UniProt ID: 
P00533) and ErbB2 (UniProt ID: P04626) were 
retrieved from Universal Protein Resource 
(UniProt), which is a comprehensive resource for 
protein sequence and annotation data. The 
three-dimensional structures of ErbB1 (PDB ID: 
4G5J) and ErbB2 (PDB ID: 3PP0) were obtained 
from Protein Data Bank (PDB). Although ErbB1 
has four isoforms, only the first isoform is 
primarily involved in lung cancer. ErbB2 has five 
isoforms. To understand the similarities and 
dissimilarities of the kinase domain of these 
isoforms, sequence comparison was performed 
for each protein separately using the Clustal 
Omega program of Uniprot. The three-
dimensional structures of both proteins were 
compared by jCE algorithm of RCSB PDB 
Protein Comparison Tool. 
 
Natural product library construction 
 
Natural products containing 6,160 compounds 
from marine sources and 18,151 compounds 
from medicinal plants were retrieved from 
previous extensive literature studies [12,13], DR. 
Duke’s Phytochemical Library (http://www.ars-
grin.gov/duke/), and PubChem BioAssay 
(http://www.ncbi.nlm.nih.gov/pcassay), which 
contains the bioactivity screens of chemical 
substances. Reference approved drug molecules 
Afatinib (DrugBank ID: DB08916) and Lapatinib 
(DrugBank ID: DB01259), as well as the 1,543 
molecules of FDA approved drugs were obtained 
from DrugBank (www.drugbank.ca). Since the 
approved drugs were selected because of their 
FDA approval, they did not require pre-clinical 
trials. DrugBank is a comprehensive, high-
quality, freely accessible, online database 
containing information on drugs and drug targets.  
 
Ligand preparation and ADME/Tox prediction 
 
The ligands used for the docking studies were 
prepared using Maestro version 9.0. It is a robust 
collection of tools designed to prepare high 
quality, all-atom 3D structures for large numbers 
of drug-like molecules, starting with 2D or 3D 
structures in SD or Maestro format. Hydrogens 
were added to the ligands. The ligand were 
desalted and tautomers were generated. 
Specified chiralities of the ligand were 
maintained. Low energy ring conformation was 
generated from each ligand. The geometry was 
optimized using forcefield OPLS 2005. The 
output file was generated in the sdf file format. 
QikProp was performed for the natural product 
molecules obtained from LigPrep. This 
application was used to determine the 
Absorption, Distribution, Metabolism, and 
Excretion (ADME) property. Thirty-one QikProp 
parameters were considered for each molecule.  
 
It is widely known that QikProp can efficiently 
evaluate pharmaceutically relevant properties for 
over half a million compounds in one hour, 
making it an indispensable lead generation and 
lead optimization tool. The descriptors 
considered were number of rotatable bonds, 
molecular weight, computed dipole moment, total 
solvent accessible surface area, total solvent-
accessible volume, number of hydrogen bond 
donor, number of hydrogen bond acceptor, 
number of likely metabolic reactions, van der 
Waals surface area of polar nitrogen and oxygen 
atoms and carbonyl carbon atoms, predicted 
central nervous system activity, hexadecane/gas 
partition coefficient, octanol/gas partition 
coefficient, water/gas partition coefficient, 
octanol/water partition coefficient, aqueous 
solubility, IC50 value for blockage of HERG K+ 
channels, apparent Caco-2 cell permeability in 
nm/sec, apparent MDCK cell permeability in 
nm/sec, brain/blood partition coefficient, binding 
to human serum albumin human oral absorption 
on 0 to 100 % scale, and conformation-
independent predicted aqueous solubility. The 
molecules that passed ADME prediction were 
used for Toxpredict procedures. Toxpredict 
(http://apps.ideaconsult.net:8080/ToxPredict) is a 
tool from the OpenTox server which calculated 
the toxicity of the natural product molecules. 
 
3D pharmacophore modelling and virtual 
screening  
 
A pharmacophore is defined as a 3D structural 
feature that illustrates the interaction of a ligand 
molecule with a target receptor in a specific 
binding site. It is possible to compute the shared 
pharmacophore feature of a known drug when its 
three-dimensional structure is available. To this 
end, virtual screening of the ligand based 3D 
pharmacophore was performed using 
LigandScout. The reference drug molecules 
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Afatinib (DrugBank ID: DB08916) and Lapatinib 
(DrugBank ID: DB01259) were optimized by 
LigPrep of Maestro version 9.0. Both the 
optimized structures were loaded onto the 
LigandScout, both structures were then aligned 
based on the pharmacophore features. Virtual 
screening was then performed with the 
generated shared feature against the natural 
products database and approved drug database 
created from the molecules obtained from the 
previous step which are passed from the in silico 
ADME prediction. The “pharmacophore-fit” 
scoring function, “match all query features” 
screening mode, and “get best matching 
conformation” retrieval mode were used for the 
pharmacophore search. The screened molecules 




Molecular docking studies were carried out for 
both the proteins separately with both the 
datasets natural product and approved drugs 
using Molegro Virtual Docker (MVD). It has two 
docking search algorithms: MolDock Optimizer 
and MolDock Simplex Evolution (SE). MolDock 
Optimizer is the default search algorithm in MVD. 
In order to dock the receptor and ligand, the 
receptor was prepared from the “prepare 
molecule” option provided. Then, for grid 
searching, cavities were generated using the 
“detect cavity” option. Finally, the ligands 
obtained from the pharmacophore studies were 
provided in an sdf file format for docking using 
the docking wizard. Default parameters with the 
grid resolution of 0.3 A were employed for 
elucidating single molecules, capable of inhibiting 
both the kinases.  
 
Visualization of results  
 
Molegro Virtual Docker (MVD) software, which is 
an integrated platform for predicting protein–
ligand interactions, was used to visualize the 
docked result. This software handles all aspects 
of the docking process from preparation of the 
molecules to determination of the potential 
binding sites of the target protein, and prediction 






The retrieved isoform sequences of ErbB1 and 
ErbB2 were aligned independently. The kinase 
domain of isoform1 of ErbB1 did not show any 
significant similarities with that of the other three 
isoforms. The kinase domains of all the five 
isoforms of ErbB2 show significant similarities. 
The three-dimensional structures of both proteins 
were compared by the jCE algorithm. The kinase 
domains of both proteins showed higher 
similarity with RMSD: 1.68, identities: 73 % and 
similarities: 83 %, indicating that a common 




It was determined from ADME/Tox prediction that 
from 24,311 natural product molecules only 
1,015 screened out were more poised. The 
significant reduction in the number of molecules 
could be attributed to the many stringent 
descriptors considered for this prediction.  
 
3D pharmacophore modelling and virtual 
Screening  
 
The structurally optimized drug molecules, 
Afatinib and Lapatinib, were aligned based on 
their pharmacophore features using 
LigandScout. Three shared features - two 
hydrophobic and one hydrogen bond acceptor - 
were obtained from both the drugs (Fig 1), which 
were considered as a query for virtual screening. 
 
The 3D pharmacophore virtual screening 
demonstrated that among the 1,015 ADME 
passed natural product molecules, only 201 
molecules have the pharmacophore features of 
both drugs, and from the 1527 approved drugs, 
356 molecules were matched with the query 
features. The ensued molecules were further 
confirmed by docking study. 
  
Molecular docking and toxicity prediction 
 
The docking studies demonstrated that only 109 
of the 201 natural product molecules and 125 of 
the 356 approved drugs have efficient binding 
with both the targets. Furthermore, only eighteen 
natural product molecules and five approved 
drugs were found to have a better docking score 
than the reference drug molecules. The two-
dimensional structure of the reference drug 
molecules, five best nontoxic natural product 
molecules and top five FDA approved drug 
molecules are shown in Figs 2(a) and 2(b). 
 
The MVD docking score is shown in Table 1. The 
selected phytochemicals had a docking score 
ranging from −144.25 Kcal/mol to -206.72 
Kcal/mol and the top ranked approved drugs had 
a docking score ranging from −139.98 Kcal/mol 
to −201.28 Kcal/mol, which is better than that of 
the reference drug molecules. 
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The docking result with hydrogen bond 
interactions are shown in Figs. 3(a) and 3(b). The 
number of hydrogen bonds and the interacting 
residues are shown in Tables 2 and 3. 
 
The reference drug molecules had one to four 
hydrogen bond interactions with the target. More 
importantly, the shortlisted phytochemicals and 
FDA approved drugs had six to twelve and one 
to eight hydrogen bond interactions, respectively. 
The docking score and number of hydrogen 
bonds of natural products and FDA approved 
drugs demonstrated higher affinity with proteins 
than the reference drug molecules. Furthermore, 
a detailed analysis of the docking results showed 
that all ligands bonded with the kinase domains 




Figure 1: The modus operandi used in the study, from pharmacophore development to virtual screening to 
molecular docking 
 
Hu et al 




Figure 2: (a) Two dimensional structure of reference drug molecules and the selected phytochemicals (b) Two 
dimensional structure of selected top five FDA approved drugs 
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Table 1: Docking score of reference drug molecules, phytochemicals, and top five FDA approved drugs with 
ErbB1 and ErbB2 
 
Name DrugBank ID / 
PubChem CID 
ErbB1 ErbB2 











Lapatinib DB01259 -143.61 -111.05 -0.46 -180.07 -154.09 0.34 
Afatinib DB08916 -135.62 -94.54 -1.08 -171.46 -145.83 -4.73 
Phytochemicals        
Hyoscyamide CID 5323554 -169.50 -107.91 -12.96 -206.72 -151.38 -12.67 
Cannabisin F CID 71448967 -152.04 -102.19 -3.22 -203.89 -129.93 -5.98 
Cochinchinenene D CID 23655937 -153.32 -12.82 -18.04 -192.07 -145.30 -11.08 
Cannabisin E CID 71448966 -144.25 -80.66 -12.30 -184.77 -134.13 -0.58 
Heliotropamide CID 637321 -166.11 -103.16 -4.53 -180.75 -89.20 -6.94 
FDA Approved drugs       
Fesoterodine DB06702 -283.38 -67.59 -3.09 -201.28 -103.16 -9.52 
Antrafenine DB01419 -155.33 -106.60 -0.86 -201.03 -164.84 -1.07 
Fluspirilene DB04842 -139.98 -86.12 -0.36 -190.66 -153.02 -5.89 
Posaconazole DB01263 -141.70 -91.79 -4.41 -190.55 -120.98 -6.10 
Iloprost DB01088 -147.13 -48.72 -5.00 -189.66 -150.88 -2.35 
 
 
Table 2: Number of hydrogen bonds and interacting residues from the docking result of reference drug molecules 
and phytochemicals 
 










Lapatinib 1 Lys 728 3 Ala 771, Gly 804, Thr 862 
Afatinib 1 Met 793 4 Gly 727, Met 801, Cys 805, Asp 808 
     
Hyoscyamide 9 
Gly 719, Ser 720, Lys 
745, Cys 775, Thr 790 (2 
hbonds), Gln 791,  
Thr 854,  Asp 855 
7 Leu 726, Gly 804, Cys 805 (3 hbonds), Glu 812, Arg 849 
Cannabisin F 8 
Lys 745, Glu 762, Cys 
797, Asp 800, Asn 842, 
ASP 855 (3 hbonds) 
12 
Gly 729, Ala 751, Lys 753, Leu 
796, Val 797, Thr 798, Gln 799, 
Leu 800,Met 801, Asp 808, Glu 





Lys 745, Cys 775, Thr790, 
Gln 791, Met 793, Gly 
796, Asn 842, Thr 854, 
Asp 855,(2 hbonds) 
6 Ser 728, Lys 753, Met 801 (2 hbonds), Arg 849, Asn 850 
Cannabisin E 7 
Gly 719, Lys 728, Pro 
794, Cys 797 (2 hbonds), 
Asp 800, His 805 
11 
Leu 726, Gly 727, Gly 729, Tyr 
803, Cys 805 (2 hbonds), Asp 
808, Glu 812, Arg 849, Asn 850, 
Thr 862 
Heliotropamide 7 
Lys 745, Pro 794, Cys 
797, Asp 800 ( 2 hbonds), 
Asn 842, Asp 855 
6 Ser 728, Gly 729, Met 801 (2 hbonds), Gly 804, Cys 805 
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Table 3: Number of Hydrogen Bonds and Interacting residues from the docking result of top five FDA approved 
drugs 
 











Fesoterodine 3 Arg 841, Asn 842, Asp 855 2 Thr 798, Gln 799 
Antrafenine 1 Cys 797 2 Gly 729, Arg 849 
Fluspirilene 1 Asp 855 5 Ala 751, Lys 753, Leu 796, Thr 862, Asp 863 
Posaconazole 4 Asp 837, Asn 842, Asp 855 (2 hbonds) 8 
Ser 783 (2 hbonds), Arg 784, Leu 
785, Thr 798, Arg 811, Thr 862, Asp 
863 
Iloprost 2 Lys 745, Thr 854 4 Ser 728 (2 hbonds), Val 797, Thr 798 
  
 
Figure 3: (a) Docking results of phytochemicals with ErbB1 and ErbB2 (b) Docking results of top five FDA 
approved drugs with ErbB1 and ErbB2 
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Molecular docking has played a key role in the 
identification of efficient binding of receptors and 
ligands. Compounds identified from docking 
studies with most favourable binding energy 
were considered as hits. Hyoscyamide, a 
secondary metabolite present in the seeds of 
Hyoscyamus niger is binding to ErbB1 and 
ErbB2 with MolDock score of -169.5 (kcal/mol) 
and -206.7 (kcal/mol) respectively. Hyoscyamide 
binding energy is the least calculated among the 
top ten compounds with ErbB2. The hydrogen 
bond forming pattern is nine hydrogen bonds 
with ErbB1 and seven with ErbB2.   Cannabisin F 
and Cannabisin E are acyclic bis-phenylpropane 
lignanamides existing in the fruits of Cannabis 
sativa. Cannabis sativa is cultivated for seed oil, 
food, and medicine. Historically, tinctures, tea, 
and ointments have also been common 
preparations. In traditional Indian medicine, C. 
sativa has been used as a hallucinogenic, 
hypnotic, sedative, an analgesic, and anti-
inflammatory agent [14]. Cannabisin E is binding 
to ErbB1 and ErbB2 with MolDock score of -
144.2 (kcal/mol) and -184.7 (kcal/mol), the 
hydrogen bond pattern with the two kinases is 
seven and eleven respectively. Cannabisin F is 
the best compound among shortlisted 
phytochemicals in terms of hydrogen bond 
pattern. Cannabisin F is forming eight hydrogen 
bonds with ErbB1 and twelve with ErbB2.  
Recently, a group of scientists from China 
synthesized cannabisin F from vanillin [15]. 
Cannabisin F has already been reported for its 
cytotoxic activity [16], and cell-growth inhibitory 
activities against human lung cancer and human 
cervical cancer [17]. Cochinchinenene D from 
Dracaena cochinchinensis has already been 
reported for its antibacterial activities against 
Helicobacter pylori [18], Dracaena 
cochinchinensis is predominant in China and its 
various other secondary metabolites are used to 
cure a variety of diseases, including 
neurodegenerative diseases, diabetes, and 
cancer[19,20]. Cochinchinenene D is forming the 
best interaction with ErbB1of ten hydrogen 
bonds, which is the best among the analyzed 
twelve compounds.  Heliotropamide from 
Heliotropium ovalifolium has oxopyrrolidine-3-
carboxamide central moiety. Heliotropamide 
among the selected phytochemicals is showing 
the least number of interaction with ErbB1 and 
ErbB2 (seven and six).  
 
The hydrogen bond binding pattern of the FDA-
approved drugs is overall lower than 
phytochemicals.  Fesoterodine, which is an 
approved drug, a prodrug is showing the best 
binding energy of -283.3 (kcal/mol) with ErbB1. 
The compound have no reported anti-cancer 
activity, however its in vivo broken down active 
metabolite: 5-hydroxymethyl tolterodine (5-HMT) 
exhibits an antimuscarinic activity by acting as a 
competitive muscarinic receptor antagonist, Both 
urinary bladder contraction and salivation are 
mediated via cholinergic muscarinic receptors 
[21]. Antrafenine is a piperazine derivative drug 
that acts as an analgesic and anti-inflammatory 
with an efficacy similar to that of naproxen, the 
compound is showing second best binding 
energy with ErbB2 among FDA-approved drugs 
and has not been reported for anti-cancer 
activity. Fluspirilene is a relatively long-acting 
injectable depot antipsychotic drug used for 
schizophrenia. It does not differ greatly from 
other depot antipsychotics (fluphenazine 
decanoate, fluphenazine enathate, perphenazine 
onanthat, pipotiazine undecylenate) with respect 
to treatment efficacy, response, or tolerability. 
Fluspirilene is showing the least potential for 
inhibiting the selected kinases among the ten 
shortlisted compounds.  Posaconazole among 
the FDA-approved drugs is showing the best 
hydrogen bond interaction with both ErbB1 and 
ErbB2. The compound exerts its antifungal 
activity through blockage of the cytochrome P-
450 dependent enzyme, sterol 14α-demethylase, 
in fungi by binding to the heme cofactor located 
on the enzyme, this leads to the inhibition of the 
synthesis of ergosterol, a key component of the 
fungal cell membrane, and accumulation of 
methylated sterol precursors, which in turn 
results in the inhibition of fungal cell growth, and 
ultimately, cell death [22]. Iloprost is a second 
generation structural analog of prostacyclin (PGI) 
with about tenfold greater potency than the first 
generation stable analogs, such as 
carbaprostacyclin. The compound is forming two 
and four hydrogen bonds with ErbB1 and ErbB2 
respectively, which is second best interaction 




The in silico approach  has helped us to  predict 
promising compounds for targeting ErbB1 and 
ErbB2 kinases with single inhibitor for the 
effective treatment of lung cancer. The approach 
provides an opportunity to focus only on selected 
compounds for further wet-lab experimental 
analysis.  
 
The generated data of the ten compounds show 
immense potential in targeting both kinases with 
single inhibitor. All the selected lead compounds 
are non-toxicity, the factor that has an immense 
role in drug discoveries. 
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